Key takeaways
Jemperli (dostarlimab-gxly) and Keytruda (pembrolizumab) are both medications used to treat certain types of cancer, and they belong to the same drug class called programmed death-1 (PD-1) pathway inhibitors. They work by helping your immune system find and attack cancer cells. Jemperli is mainly FDA approved for endometrial cancer and other solid tumors with specific abnormalities, while Keytruda is approved for a wider range of cancers, including non-small cell lung cancer, melanoma, and breast cancer. Jemperli is given as an infusion every 3 or 6 weeks, depending on your treatment plan, and is often used with other chemotherapy for endometrial cancer. Keytruda is also given as an infusion every 3 or 6 weeks, but it can be used alone or with other anticancer therapies. Both medications can cause immune-related side effects like rash, diarrhea, and high blood sugar. Neither medication is available as a generic, and both require careful monitoring by your healthcare team to manage side effects and ensure the best treatment outcome.
